ALVR106 / Kalaris Therapeutics, Baylor College of Medicine - LARVOL DELTA

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant (clinicaltrials.gov) - P1/2 | N=16 | Terminated | Sponsor: AlloVir | N=77 ➔ 16 | Trial completion date: Jun 2024 ➔ Jan 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2023 ➔ Jan 2024; Strategic sponsor decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Influenza • Respiratory Diseases • Respiratory Syncytial Virus Infections • Solid Organ Transplantation • Transplantation

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial (TCT-ASTCT-CIBMTR 2024) - "ALVR106 was safe and well tolerated, supporting its continued evaluation in HCT and SOT recipients."

P1 data • Virus specific T cells • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Solid Organ Transplantation • Transplantation

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial (ASH 2023) - "In this ongoing trial-the first-in-human, double-blind, PBO-controlled trial of virus-specific T cell therapy in transplant recipients with respiratory infection-ALVR106 was safe and well tolerated, supporting its continued evaluation in HCT and SOT recipients."

P1 data • Virus specific T cells • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Solid Organ Transplantation • Transplantation • IFNG

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell Transplant (clinicaltrials.gov) - P1/2 | N=77 | Recruiting | Sponsor: AlloVir | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2021 ➔ Mar 2022

Enrollment open • Trial initiation date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience (Businesswire) - "AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster presentation during the Transplantation & Cellular Therapy Meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) taking place virtually February 8 – 12, 2021."

Clinical data • Infectious Disease • Novel Coronavirus Disease

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell Transplant (clinicaltrials.gov) - P1/2; N=77; Not yet recruiting; Sponsor: AlloVir

Clinical • New P1/2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation • CD4 • HLA-DRB1

AlloVir Reports Third Quarter 2020 Financial Results (GlobeNewswire) - "ALVR109 Program Highlights: Initial clinical trial manufacturing runs of ALVR109 have been released and the proof-of-concept clinical trial with ALVR109 has been initiated; Pre-clinical data on this program will be presented in an oral session at ASH and will be featured in the conference press program. ALVR106 Program Highlights....The POC clinical trial will now initiate in 2021 as the company is assessing the impact of the COVID-19 pandemic on the incidence, diagnosis and treatment of the respiratory viral infections which ALVR106 targets."

New trial • Preclinical • Trial status • Infectious Disease • Novel Coronavirus Disease

BAT IT: Anti-SARS Cov-2 T Cell Infusions for COVID 19 (clinicaltrials.gov) - P1; N=58; Recruiting; Sponsor: Baylor College of Medicine; Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • PCR

AlloVir expands its research collaboration with Baylor College of Medicine to discover and develop allogeneic, off-the-shelf, virus-specific T-cell therapies for Covid-19 (Businesswire) - "AlloVir...collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2....AlloVir aims to develop a therapy for CoVs that can be used as a stand-alone treatment or incorporated into the company’s multi-respiratory virus investigational therapy, ALVR106."

Licensing / partnership • Preclinical